CLDX — CELLDEX THERAPEUTICS

Ownership history in Bellevue Group AG  ·  15 quarters on record

This page tracks every 13F SEC filing in which Bellevue Group AG reported a position in CELLDEX THERAPEUTICS (CLDX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
1.91% (2025 Q3)
Avg. % of fund
1.3%
First filed
2022 Q2
Last filed
2025 Q4
Quarters held
15
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 3,617,669 +60,000 +1.7% 1.86% $98.3M $27.16
2025 Q3 ADDED 3,557,669 +250,100 +7.6% 1.91% $92.0M $25.87
2025 Q2 ADDED 3,307,569 +235,954 +7.7% 1.48% $67.3M $20.35
2025 Q1 UNCHANGED 3,071,615 — 0% 1.25% $55.7M $18.15
11 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    CLDX price (monthly, adj. close)

Other funds also holding CLDX

As of 2025 Q4 — sorted by position size

Kynam Capital Management, LP 3Y 10.31% Elmind Capital, LP 6.93% Commodore Capital LP 3Y 4.64% 5AM Venture Management, LLC 3Y 4.25% Propel Bio Management, LLC 3.58% GordonMD Global Investments LP 3.32% Novo Holdings A/S 3Y 7Y 2.53% TSP Capital Management Group, LLC 3Y 7Y 2.49% Eversept Partners, LP 3Y 7Y 1.96% BRAIDWELL LP 3Y 1.61%
← Back to Bellevue Group AG Holdings